U.S. District Court invalidates Heron's CINVANTI patents; company plans appeal

A Delaware federal court ruled that Heron Therapeutics' U.S. Patent Nos. 12,115,255 and 12,290,520 for CINVANTI injectable emulsion are invalid in litigation against Azurity Pharmaceuticals. The decision threatens Heron's intellectual property protection for a key product, though the company plans to appeal to the Federal Circuit and stated the ruling does not impact existing settlement agreements.